Moderna to Present at the 44th Annual J.P. Morgan Healthcare Conference

Moderna to Present at the 44th Annual J.P. Morgan Healthcare Conference

CAMBRIDGE, MA / ACCESS Newswire / December 17, 2025 / Moderna, Inc. (Nasdaq:MRNA) today announced it will present at the 44th annual J.P. Morgan Healthcare Conference on Monday, January 12th at 7:30 p.m. ET / 4:30 p.m. PT.

A live webcast of the presentation will be available under "Events and Presentations" in the Investors section of the Moderna website at investors.modernatx.com.

A replay of the webcast will be archived on Moderna's website for at least 30 days following the presentation.

About Moderna

Moderna is a pioneer and leader in the field of mRNA medicine. Through the advancement of its technology platform, Moderna is reimagining how medicines are made to transform how we treat and prevent diseases. Since its founding, Moderna's mRNA platform has enabled the development of vaccines and therapeutics across infectious diseases, cancer, rare diseases and more.

With a global team and a unique culture, driven by the company's values and mindsets, Moderna's mission is to deliver the greatest possible impact to people through mRNA medicines. For more information about Moderna, please visit modernatx.com and connect with us on X, Facebook, Instagram, YouTube and LinkedIn.

Investors:
Lavina Talukdar
Senior Vice President & Head of Investor Relations
617-209-5834
Lavina.Talukdar@modernatx.com

SOURCE: Moderna, Inc.



View the original press release on ACCESS Newswire

News Provided by ACCESS Newswire via QuoteMedia

MRNA
The Conversation (0)
InMed to Present INM-901 Data at Alzheimer's Association International Conference  2025

InMed to Present INM-901 Data at Alzheimer's Association International Conference 2025

Long-term INM-901 treatment in preclinical studies in advanced disease continues to show multi-modal activityInMed Pharmaceuticals Inc. (NASDAQ: INM) ("InMed" or the "Company"), a pharmaceutical company focused on developing a pipeline of proprietary small molecule drug candidates for diseases... Keep Reading...
InMed Reports Second Quarter Fiscal 2025 Financial Results and Provides Business Update

InMed Reports Second Quarter Fiscal 2025 Financial Results and Provides Business Update

InMed Pharmaceuticals Inc. (NASDAQ: INM) ("InMed" or the "Company"), a pharmaceutical company focused on developing a pipeline of proprietary small molecule drug candidates for diseases with high unmet medical needs, today reports financial results for the second quarter of the fiscal year 2025... Keep Reading...
InMed's INM-901 Demonstrates Statistically Significant Reduction in Neuroinflammation in a Long-Term Preclinical Alzheimer's Disease Study

InMed's INM-901 Demonstrates Statistically Significant Reduction in Neuroinflammation in a Long-Term Preclinical Alzheimer's Disease Study

INM-901 significantly reduced pro-inflammatory cytokines associated with Alzheimer'sStatistically significant reduction in neurodegeneration marker, neurofilament light chain ('NfL')mRNA profile showed a reduction of several key neuroinflammatory genes in the brainInMed Pharmaceuticals Inc.... Keep Reading...

Interactive Chart

Latest Press Releases

Related News